SkylineDx presents landmark findings from the largest prospective multicenter melanoma GEP trial at SSO 2025
High clinical impact in subgroups – Merlin Low Risk patients show high negative predictive value (NPV), while Merlin High Risk patients exceed SLNB recommendation thresholds.
ROTTERDAM, Netherlands and SAN DIEGO, March 28, 2025 /PRNewswire/ -- SkylineDx, an innovative diagnostics company specializing in the research and development of molecular diagnostics for oncology , inflammatory and infectious diseases, proudly announces Dr. Tina Hieken, a surgical oncologist at Mayo Clinic and one of the principal investigators of the groundbreaking MERLIN_001 study, will present new data at the 2025 Society of Surgical Oncology (SSO) Annual Meeting [1]. Dr. Hieken's presentation, titled Prospective Multicenter Evaluation (MERLIN_001 Trial) of a Clinicopathologic and Gene Expression Profile Test to Predict Sentinel Node Status in T1-T3 cN0 Melanoma, will showcase the final results of this pivotal study, which demonstrates the accuracy of the Merlin CP-GEP test in predicting sentinel lymph node (SLN) metastases in melanoma patients.
The MERLIN_001 trial is the largest prospective, blinded study, to evaluate the Merlin CP-GEP test, which is the only commercially avialable GEP test that combines clinical, pathological, and gene expression data into a single algorithm to predict SLN positivity. The study was conducted at 9 renowned US hospitals, which are also top-ranking oncology academic centers. The study's findings validate the test's superior predictive accuracy compared to traditional clinical and pathological factors, which currently guide sentinel lymph node biopsy (SLNB) decisions in melanoma.
A total of 1,802 patients were included for whom SLN biopsy material was available. CP-GEP achieved an assay success rate of 97.7%, thus a total of 1,761 patients could be enrolled. The National Comprehensive Cancer Network (NCCN) clinical guidelines recommend SLNB surgery for patients with >10% risk of nodal metastases. This cohort had a 17.6% overall SLNB positivity rate, suggesting effective referral of patients based on current factors. However, 82.4% of patients had a negative sentinel node suggesting no therapeutic benefit from the sentinel node operation.
How did Merlin CP-GEP test provide more precise risk stratification, allowing physicians to further optimize SLNB referral decisions and personalize treatment plans? Key findings from the MERLIN_001 study:
In this cohort a total of 31 T1a patients with adverse features were referred for SLNB surgery. Merlin identified 80.6% as Low Risk for nodal metastases at a negative predictive value (NPV) of 100%. These patients could consider forgoing SLNB surgery as their risk of nodal metastases is close to 0%. Six patients were identified as Merlin High Risk. Their risk of metastases was with 16.7% well above the >10% guideline threshold, therefore these patients should be referred for surgery.
Among the 479 T1b patients, Merlin test identified 67.6% as Low Risk for nodal metastases with a 94.8% NPV. These patients could consider forgoing SLNB surgery as their risk of metastases is close to 5%. Additionally, T1b patients with a Merlin High Risk label had a 16.1% SLNB positivity rate and should be referred for surgery.
The study's findings are particularly significant for T2a melanoma patients. This patient subgroup had an SLN positivity rate of 15.5%. Merlin test identified 36.6% as Low Risk at an NPV of 91.9%, reducing their metastatic risk below the 10% threshold for SLNB surgery recommendation. Reclassification of these T2a patients gives them access to more personalized treatment options.
The Merlin CP-GEP test also demonstrated exceptional performance in other subgroups, particularly in head and neck melanoma patients. SLNB surgery in this group poses unique challenges due to complex lymphatic drainage and vital anatomical structures. Merlin test identified 43.3% as Low Risk for nodal metastases with an NPV of 95.1%. These patients could consider forgoing SLNB surgery as their risk of metastases is below 5%.
"The MERLIN_001 study provides a transformative approach to melanoma risk assessment, ensuring that we can better personalize care for our patients. The test not only refines risk stratification but also addresses critical subgroups, such as head and neck melanoma patients and elderly individuals, who often face complex treatment decisions. By leveraging this groundbreaking tool, we can confidently guide SLNB recommendations and optimizing patient outcomes," said Dr. Tina Hieken.
"The MERLIN_001 study results are a breakthrough in melanoma care," said Dharminder Chahal, CEO of SkylineDx. "As the only company to have conducted this large, prospective, blinded trial of the Merlin CP-GEP test in collaboration with esteemed academic institutions in the U.S., we are committed to empowering clinicians with a rigorously validated test backed by high-quality evidence, ensuring patients receive the most informed care possible ."
The MERLIN_001 study represents a major milestone in melanoma research, with the potential to enhance clinical decision-making and improve patient outcomes. By offering more accurate risk assessments, the Merlin CP-GEP test empowers healthcare providers to tailor treatment plans to the specific needs of melanoma patients.
About the advanced cutaneous melanoma GEP test (Merlin CP-GEP test) CP-GEP is a non-invasive prediction model for cutaneous melanoma patients and is the only commercially available GEP test that combines clinicopathologic (CP) variables with gene expression profiling (GEP) into a single integrated algorithm. This CP-GEP model is also the only GEP test that provides a binary stratification of all patients based on being High or Low Risk for metastasis and thereby assign them to the appropriate surgical action categories as listed in evidence-based cancer treatment, prevention and screening guidelines. The advanced generation CP-GEP model was developed by Mayo Clinic and SkylineDx BV and is the latest commercially launched GEP test, which has been clinically validated in multiple studies on a global basis. More information (including references) may be obtained at www.falconprogram.com and www.merlinmelanomatest.com. The test has been launched in the United States and Europe as Merlin test. SkylineDx collaborates with diagnostic service providers globally to bring this test to market and increase patient access.
About SkylineDx SkylineDx is a biotechnology company focused on research & development of molecular diagnostics in oncology inflammatory, and infectious diseases. SkylineDx uses its expertise to bridge the gap between academically discovered gene expression signatures and commercially available diagnostic products with high clinical utility, assisting healthcare professionals in accurately determining the type or status of disease or predicting a patient's response to treatment. Based on test results, healthcare professionals can tailor the treatment approach to the individual patient. SkylineDx is headquartered in Rotterdam. the Netherlands, complemented by a U.S. base of operations and a CAP/CLIA certified laboratory in San Diego California, USA. To learn more about SkylineDx, please visit www.skylinedx.com.
Footnotes:
1. T. Hieken et. al. Prospective multicenter evaluation (MERLIN_001 trial, NCT04759781) of a clinicopathologic and gene expression profile test to predict sentinel node status in T1-T3 cN0 melanoma SSO-2025-Heiken.pdf
View original content:https://www.prnewswire.com/news-releases/skylinedx-presents-landmark-findings-from-the-largest-prospective-multicenter-melanoma-gep-trial-at-sso-2025-302414214.html
SOURCE SkylineDx
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Global Healthcare Gets a 6G Boost: Market to Grow at 77.9% CAGR Through 2040
"This report explores how 6G is poised to reshape global healthcare through innovations in remote patient monitoring, AR/VR diagnostics, robotic surgeries, and smart hospital infrastructure, powered by ultra-low latency, AI integration, and massive device connectivity." BOSTON, Aug. 20, 2025 /PRNewswire/ -- According to the latest study from BCC Research, the "6G in Healthcare: Global Market" is projected to reach $194 billion by the end of 2040 with a CAGR of 77.9% from 2031 to 2040. The report analyzes the global 6G market in healthcare, exploring trends, challenges, and growth drivers. It segments the market by component, application, connectivity, end user, and region, covering the major areas of North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. Additionally, it evaluates the competitive landscape by ranking leading companies and profiling major players. This report is especially relevant now as the global momentum toward digital healthcare transformation continues to grow, and research into 6G technology rapidly advances. It provides timely insights into how 6G is poised to revolutionize healthcare by enhancing delivery, boosting efficiency, and driving innovation. For early adopters and stakeholders, understanding these developments is crucial to staying ahead in a highly competitive and evolving landscape. The factors driving the market's growth include: Rising Demand for Enhanced Healthcare Services and Efficiency: Healthcare systems are under pressure to deliver faster, more personalized, and cost-effective care. 6G can support this by enabling real-time diagnostics, AI-powered decision-making, and seamless telemedicine experiences, ultimately improving service quality and operational efficiency. Growing Adoption of IoT and Connected Devices in Healthcare: The increasing use of wearables, smart medical equipment, and remote monitoring tools is transforming healthcare. 6G will enhance these technologies by offering faster data transmission, better connectivity, and improved energy efficiency, creating a smarter and more responsive healthcare ecosystem. Need for Ultra-Reliable and Low-Latency Communication for Critical Applications: In life-critical scenarios like remote surgeries or emergency response, reliability and speed are essential. 6G's ultra-low latency and high reliability ensure uninterrupted, secure communication, making it ideal for mission-critical healthcare applications. Request a sample copy of the global market trends for 6G in healthcare report. Report Synopsis Report Metric Details Base year considered 2030 Forecast period considered 2031-2040 Base year market size $664.2 million Market size forecast $194.0 billion Growth rate CAGR of 77.9% from 2031 to 2040 Segments covered Component, Application, Connectivity Type, End User, and Region Regions covered North America, Europe, Asia-Pacific, South America, and the Middle East and Africa (MEA) Countries covered U.S., Canada, Mexico, Brazil, Argentina, Japan, China, India, South Korea, Australia, Rest of Asia-Pacific, Germany, U.K., France, Italy, Spain, Rest of Europe, the Middle East, and Africa Market drivers • Rising demand for enhanced healthcare services and efficiency. • Growing adoption of IoT and connected devices in healthcare. • Need for ultra-reliable and low-latency communication for critical applications. Interesting facts: 6G technology is expected to be 100 times faster than 5G, enabling real-time remote surgeries, seamless medical data transmission, and continuous biometric streaming via wearables for predictive healthcare analytics. It will also support digital twins, the virtual patient models that allow doctors to simulate treatments before applying them in real life. The integration of AI and 6G could dramatically reduce emergency response times through intelligent, connected systems. South Korea and China are among the countries already investing in national initiatives to lead 6G healthcare innovations by 2030. The report addresses the following questions: 1. What are the projected size and growth rate of the market? The global market for 6G in healthcare is projected to reach $194 billion by the end of 2040, with a CAGR of 77.9%. 2. Which factors are driving the growth of the market? The growth of 6G in the healthcare market is driven by increasing demand for real-time patient monitoring and data-intensive applications. Advances in AI and IoMT are enhancing diagnostic precision and care delivery through ultra-fast connectivity. The rising adoption of telehealth and remote surgeries requires the low latency and high reliability that 6G offers. Growing investments in smart hospitals and digital infrastructure further propel the market expansion for 6G. 3. Which market segments are covered in the report? The market in this report is segmented by component, application, connectivity, and end user. 4. Which component segment will be dominant through 2040? The hardware segment will dominate the market for 6G in healthcare. 5. Which region has the highest market share? The North America market for 6G in healthcare was valued at $201.3 million in 2030 and is projected to reach $52.6 billion in 2040, at a CAGR of 76.0% during the forecast period. Market leaders include: APPLE AT&T CISCO SYSTEMS HUAWEI TECHNOLOGIES CO. LTD. INTEL MICROSOFT NOKIA QUALCOMM TECHNOLOGIES INC. SAMSUNG SIEMENS HEALTHINEERS AG Purchase a copy of the report direct from BCC Research. For further information on any of these reports or to make a purchase, contact info@ About BCC Research BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype. Contact UsCorporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USAEmail: info@ +1 781-489-7301 For media inquiries, email press@ or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. Logo: View original content to download multimedia: SOURCE BCC Research LLC Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
Signos Unveils First Ever FDA-Cleared Glucose Monitoring Breakthrough for Weight Management, Enabling Millions of Americans to Take Control of Their Health
PALO ALTO, Calif., Aug. 20, 2025 /PRNewswire/ -- Signos, a purpose-driven metabolic health platform committed to transforming lives through personalized, real-time insights, today announced the launch of Signos Glucose Monitoring System, the first ever FDA-cleared, over-the-counter glucose monitoring system for weight management. At a time when obesity and disease threaten the well-being of millions, Signos is leading the movement to put metabolic health back into the hands of individuals. By integrating Stelo by Dexcom glucose biosensor with an AI-powered platform for deciphering unique metabolisms, Signos enables people to see how food choices, timing, activity, stress, and even sleep affect their bodies in real time — equipping them with the information required to seize their health and make decisions backed by their own biology. "This is more than a product launch — it's a mission," said Sharam Fouladgar-Mercer, CEO and Founder of Signos. "Everyone deserves access to insights that help them live healthier, longer, more vibrant lives. Signos isn't just about data; it's about giving people ownership over their health and weight journeys in a way never before seen." Key Features and Purpose-Driven Benefits: Igniting the Metabolic Movement with Personalized Data: By tapping into the body's own signals, Signos equips individuals with tools to improve sleep, manage weight, and reduce the risk of chronic disease — not through restriction, but through understanding. Personalized, AI-Driven Insights: Signos translates glucose fluctuations into easy-to-follow, personalized recommendations — transforming raw data into actionable guidance for building healthier everyday habits. Total Body Intelligence: Signos helps users understand how their bodies respond to meals, workouts, sleep, and stress, creating a holistic picture of personal health. Expert Metabolic Monitoring: Signos removes barriers and puts powerful glucose insights into the hands of millions without the need for prescriptions, inflated prices, or hidden hoops. It's real-time metabolic health, made truly accessible. The need for accessible, effective metabolic health solutions has never been greater. With 73.6% of U.S. adults classified as overweight or obese, 88% of Americans classified as metabolically unhealthy, and global diabetes diagnoses projected to reach 1.3 billion by 2050, Signos offers a proactive solution grounded in science and is changing the trajectory of metabolic health by intervening early and guiding users toward meaningful, lasting lifestyle changes. The company aims to help millions monitor their metabolic health and build better habits by leveraging insights based on glucose, the body's primary energy source. Raven-Symoné, actress and advisor, shared, "I've been using Signos for years now and no matter my mental ups and downs it is there to keep me in reality. The reality is things change, levels change, but if you keep an eye on the overall picture you can keep your health in the green. Signos gives me the confidence to enjoy life while being mindful of my body and what it needs." Signos is available now, offering individuals everywhere a revolutionary way to monitor glucose, unlock personalized insights, and take control of their metabolism to build a sustainably healthier life — all from the convenience of their smartphone. For more information, visit View original content to download multimedia: SOURCE Signos
Yahoo
2 hours ago
- Yahoo
IBM and NASA Release Groundbreaking Open-Source AI Model on Hugging Face to Predict Solar Weather and Help Protect Critical Technology
The first heliophysics AI foundation model trained on high resolution solar observation data offers insights into the Sun's dynamic surface, helping plan for solar weather that can disrupt technology on Earth and in space Openly available on Hugging Face, the model was built to speed up scientific discovery and democratize AI for the global research and technology community Researchers also release the largest known curated heliophysics dataset to advance data driven space weather research YORKTOWN HEIGHTS, N.Y., Aug. 20, 2025 /PRNewswire/ -- IBM (NYSE: IBM) and NASA today unveiled the most advanced open-source foundation model designed to understand high resolution solar observation data and predict how solar activity affects Earth and space-based technology. Surya, named for the Sanskrit word for the Sun, represents a significant advancement in applying AI to solar image interpretation and space weather forecasting research, providing a novel tool to help protect everything from GPS navigation to power grids to telecommunications from the Sun's ever-changing nature. The Sun may be 93 million miles away, but its impact on modern life is immediate and growing. Solar flares and coronal mass ejections can knock out satellites, disrupt airline navigation, trigger power blackouts, and pose serious radiation risks to astronauts. With humanity's increasing dependence on space-based technology and plans for deeper space exploration, accurate solar weather prediction has become critical. As humanity's technological dependence grows, so does our vulnerability to space weather. According to a systemic risk scenario created by Lloyd's, the global economy could be exposed to losses of $2.4 trillion over a five-year period, with the expected loss of $17 billion from the threat of a hypothetical solar storm. Recent solar events1 have already demonstrated the risk, disrupting GPS services, forcing flight diversions, and damaging satellites. The effects of solar storms can cause: Damage to satellites, spacecraft and/or astronauts that are stationed beyond Earth Loss of satellite hardware, damaging solar panels and circuits Impact to airline travel, due to navigational errors and potential risk of radiation for airline crew and passengers Lowered food production as agriculture can be impacted by disrupted GPS navigation The implications include both academic research and operational preparedness. The new model will provide tools to help experts plan for solar storms, which can disrupt the Earth's technological infrastructure. "Think of this as a weather forecast for space," said Juan Bernabe-Moreno, Director of IBM Research Europe, UK and Ireland. "Just as we work to prepare for hazardous weather events, we need to do the same for solar storms. Surya gives us unprecedented capability to anticipate what's coming and is not just a technological achievement, but a critical step toward protecting our technological civilization from the star that sustains us." Traditional solar weather prediction relies on partial satellite views of the Sun's surface, historically making accurate forecasting extremely difficult. Surya addresses this typical limitation by training on the largest curated high resolution heliophysics dataset. This dataset is designed to help researchers better study and evaluate critical space weather prediction tasks. Examples of these tasks, which Surya has been tested on, include predicting solar flares, the speed of solar winds, solar EUV spectra prediction and the emergence of active regions on the Sun. In early testing, researchers report achieving a 16 percent improvement in solar flare classification accuracy, which researchers report as a very substantial improvement compared to previous methods. In addition to the binary solar flare classification task, Surya is built to visually predict solar flares for the first time, providing a high resolution image of where the flare is predicted to occur up to two hours out. The technical challenges were immense. Surya was trained on nine years of high-resolution solar observation data from NASA's Solar Dynamics Observatory. These solar images are 10 times larger than typical AI training data, requiring a custom multi-architecture solution to handle the massive scale while maintaining efficiency. The result is a model with unprecedented spatial resolution that can resolve solar features at scales and contexts not previously captured in large-scale AI training workflows. "We are advancing data-driven science by embedding NASA's deep scientific expertise into cutting-edge AI models," said Kevin Murphy, chief science data officer at NASA Headquarters in Washington. "By developing a foundation model trained on NASA's heliophysics data, we're making it easier to analyze the complexities of the Sun's behavior with unprecedented speed and precision. This model empowers broader understanding of how solar activity impacts critical systems and technologies that we all rely on here on Earth." Surya is part of a broader effort at IBM to embrace generative and automated approaches that empower algorithms to be discovered, tested, and evolved at scale. Surya is one example of how IBM is positioning AI not just as a tool, but as a driver of scientific discovery. By releasing Surya on Hugging Face, IBM and NASA are democratizing access to advanced tools for understanding and forecasting solar weather and scientific exploration. Researchers worldwide can now build upon this foundation to develop specialized applications for their regions and industries. This model is part of a larger collaboration between IBM and NASA to use AI technology to explore our planet and solar system. It joins the Prithvi family of foundation models, which includes a geospatial model and a weather model. Last year, IBM and NASA released the Prithvi weather model on Hugging Face for scientists and the broader community to develop short- and long-term weather and climate projections. About IBMIBM is a leading provider of global hybrid cloud and AI, and consulting expertise. We help clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. Thousands of government and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM's hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM's breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and consulting delivers open and flexible options to our clients. All of this is backed by IBM's long-standing commitment to trust, transparency, responsibility, inclusivity and service. Media ContactAshley PetersonIBM Research 1 Interplanetary Causes and Impacts of the 2024 May Superstorm on the Geosphere: An Overview – IOPscience. Interplanetary Causes and Impacts of the 2024 May Superstorm on the Geosphere: An Overview, Hajra, Rajkumar, Tsurutani, Bruce Tsatnam, Lakhina, Gurbax Singh, Lu, Quanming, Du, Aimin. View original content to download multimedia: SOURCE IBM
